ACSL4 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, featuring targeted disruption of the ACSL4 gene. This loss-of-function model enables the functional study of ACSL4-dependent processes without the constraints of clonal selection, providing a heterogeneous cellular background that more closely mimics biological variability. The use of CRISPR/Cas9 technology ensures a robust gene disruption across the cell pool, generating a reliable system for investigating the downstream consequences of ACSL4 deficiency.
The A-549 cell line, originally established from a human lung adenocarcinoma, is a widely employed epithelial model in cancer research, drug development, and respiratory disease studies. These cells retain key characteristics of alveolar epithelial type II cells, including the expression of surfactant proteins and the capacity for metabolic and signaling studies relevant to lung cancer biology. Their tumorigenic background and well-documented response to chemotherapeutics and targeted agents make them particularly suitable for ferroptosis and metabolic reprogramming investigations.
ACSL4 catalyzes the ATP-dependent activation of long-chain polyunsaturated fatty acids (PUFAs), such as arachidonic acid, to their acyl-CoA derivatives (PUFA-CoAs), which are preferentially channeled into membrane phospholipids. This enrichment of phospholipids with oxidizable polyunsaturated acyl chains primes cells for lipid peroxidation and ferroptosis. ACSL4 expression is transcriptionally regulated by SREBP1c, PPARgamma, LXR, and HIF-1alpha, integrating nutrient and stress signals. Functionally, ACSL4 acts upstream of lipid peroxidation; its activity promotes the generation of phospholipid peroxides, while its deficiency attenuates ferroptotic responses. ACSL4 directly interacts with ACSL family members, CPT1A, GPX4, and ALOX enzymes, forming a network that controls lipid metabolism and oxidative cell death. In the presence of GPX4 inhibition or oxidative stress, ACSL4-driven PUFA-phospholipids become substrates for ALOX-mediated peroxidation, leading to membrane damage and ferroptotic cell death.
In the A-549 lung adenocarcinoma context, endogenous ACSL4 contributes to the baseline lipidomic landscape and ferroptosis sensitivity. Disruption of ACSL4 in these cells provides a critical model to dissect how lung cancer cells modulate lipid metabolism to evade ferroptosis, a process implicated in therapeutic resistance. This knockout population allows researchers to evaluate the impact of ACSL4 loss on cancer cell viability, lipid reprogramming, and response to ferroptosis-inducing agents, offering insights into potential vulnerabilities of ferroptosis-resistant tumors.
Research applications include mechanistic studies of ferroptosis regulation, investigation of cancer drug resistance, metabolic reprogramming analysis, and validation of therapeutic targets in lipid-dependent cell death pathways. Typical assays for this model encompass western blotting and RT-qPCR for confirming ACSL4 ablation, lipid peroxidation detection using C11-BODIPY, ferroptosis cell death assays, lipidomics analyses to characterize global lipid alterations, and drug sensitivity testing. For further details and ordering information, please contact Ascent Research.
